Athena Pharmaceutiques SAS

NFL BIOSCIENCES: PATENT APPLICATION FILED IN THE UNITED STATES FOR REDUCING ALCOHOL CONSUMPTION WITH NFL-301 & PREPARATION OF A PRE-IND APPLICATION SUBMISSION WITH THE FDA NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, is announcing that it has today submitted a patent application in the United States for its drug candidate NFL-301, focused on reducing alcohol consumption. This patent application submission is a precondition for a pre-IND application with the FDA in the United States1 and a commitment to extending this new patent application internationally. Patent application filed in the United States for the formulation of NFL-301 and commitment to extend it internationally NFL Biosciences is continuing to move forward with its intellectual property strategy with the filing of a first patent for NFL-301. It aims to protect prolonged-release formulations of extracts of kudzu, a plant used in traditional Chinese medicine, as well as their uses for the treatment of alcohol consumption reduction. Under the co-development agreement set up at the start of 2022, NFL Biosciences and its industrial partner ATHENA Pharmaceutiques have developed a prolonged-release form of kudzu extracts in microgranule form, NFL-301. NFL Biosciences aims to develop the first oral delivery drug based on kudzu extracts to tackle excessive alcohol consumption. NFL-301 will stand out from kudzu-based nutritional supplements through: its positioning as a drug that is compliant with marketing authorization (MA) regulations;its dosage that is higher and in line with the expected efficacy range in the countries that limit daily concentrations as a nutritional supplement (e.g. France, Belgium and other European countries);its quality, controlled in accordance with good manufacturing practices (GMP);its prolonged effect enabling a single daily dose;its flexibility for taking and adapting dosage levels thanks to the microgranule form, compared with capsules or tablets. Preparation of a pre-IND application in the United States for NFL-301 NFL is preparing a pre-IND application in the United States, which is expected to be submitted in September, with a view to obtaining FDA approval for the manufacturing process, product quality and development strategy through to MA. This project is being carried out working with Prof. Scott Lukas, Director of the Behavioral Psychopharmacology Research Laboratory and the McLean Hospital Imaging Center at Harvard Medical School in Boston, who is a world-renowned addiction research specialist and has led recent clinical trials covering the effect of the administration of kudzu extracts in terms of reducing alcohol consumption: “I am delighted with NFL Biosciences’ development of a prolonged-release form of pharmaceutical grade kudzu extract. We had reached the clinical development limits with the traditional forms. This formulation should enable us to continue developing this potentially disruptive treatment, because, to date, it has been very well tolerated, free from side-effects and effective”. Bruno Lafont, Chief Operating Officer leading the scientific development of the Company’s projects: “We would like to sincerely thank Athena Pharmaceutiques for the development of this formulation, which is the result of 18 months of work, as well as Ipsilon and Francis Ahner, a member of our Board of Directors and global intellectual property expert, for the preparation of this patent application. The clear commitment that we set out when we listed on the stock market to develop a second drug candidate in addition to NFL-101 is gradually being confirmed and it is expected that further progress will be established by the end of the year”. About NFL Biosciences NFL Biosciences is a biopharmaceutical company based in the Montpellier area which develops botanical drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, natural, safer and more effective therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, called NFL-101, is a standardized, nicotine free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who want to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorder. The shares of NFL Biosciences are listed on Euronext Growth Paris (FR0014003XT0 – ALNFL). Find out more at www.nflbiosciences.com Contacts Bruno Lafont – info@nflbiosciences.com - +33 4 11 93 76 67 Agence Calyptus – nflbiosciences@calyptus.net - +33 1 53 65 68 68 1 The pre-IND application (Pre-Investigational New Drug (IND) Application) with the Food and Drug Administration (FDA) aims to prepare, through early communications between companies and the FDA’s new drug review divisions, the data necessary to warrant IND submission. Attachment 20230718_NFLBiosciences_brevet-NFL-301_EN_vFinale

NFL Biosciences: 2022 full-year business and earnings update Phase II/III clinical trial for the drug candidate NFL-101 for smoking cessation: 100% of volunteers recruited. Initial results expected in the fourth quarter of 2023 Progress with the PRECESTO clinical trial to demonstrate the potential complementarity of NFL-101 with other smoking cessation treatments: final recruitment in the second quarter and initial results expected in the third quarter of 2023 Co-development agreement continuing to move forward for NFL-301, a drug candidate to reduce alcohol consumption Intellectual property extended with a patent granted in China and South Korea and a new patent application submitted in the United States Diversified sources of financing set up at the start of 2023: cash runway to the third quarter of 2024 NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, is reporting its full-year results for 2022, as approved by the Board of Directors on April 24, 2023. At this time, NFL Biosciences looks back on its many areas of progress for its drug candidates and the success of its financing strategy, with cash requirements covered through to the third quarter of 2024. Ignacio Faus, NFL Biosciences Chairman of the Board and Chief Executive Officer: “We are proud to announce the completion of the recruitment of the 318 volunteers taking part in our most important clinical study with NFL-101 for smoking cessation. The study, code-named CESTO II, was put in place following our initial public offering on Euronext Growth Paris in July 2021. The many advances made since this transaction contributed to the success of the €3.1m fundrasing round carried out in January 2023, while also enabling us to obtain non-dilutive financing with public organizations supporting research in France. Our financial position is therefore secured through to the third quarter of 2024 and we can confidently continue, to develop our two priority drug candidates, NFL-101 and NFL-301. The coming quarters will of course be decisive for assessing the efficacy of NFL-101, with the initial results expected by the end of the year. We are moving forward with confidence into a key scientific period, in order to execute our business plan”. Phase II/III clinical trial for the drug candidate NFL-101 for smoking cessation: 100% of volunteers recruited and initial results planned for the fourth quarter of 2023 Approved in France by the French National Agency for the Safety of Medicines and Health Products (ANSM), the NFL-101 CESTO II Phase II/III clinical trial received a favorable opinion from the French Ethical Review Board (CPP) in September 2021. NFL-101 is a standardized version for pharmaceutical use derived from a natural product, initially developed by the Institut Pasteur for tobacco allergies among people working in tobacco factories. CESTO II’s objectives are to select the best dose and assess the efficacy of NFL-101 versus placebo, based on various primary and secondary criteria set by the Food & Drug Administration (FDA) for the United States and the European Medicines Agency (EMA) for Europe. Patient recruitment started in January 2022, gradually mobilizing a total of eight Clinical Investigation Centers (CIC) at CHU university hospital centers (Bordeaux, Clermont-Ferrand, Dijon, Lorient, Marseille, Montpellier, Poitiers and Rennes), as well as the Eurofins-Optimed research institute (Grenoble). The final recruitments were completed by the end of April 2023. In terms of funding for CESTO II, NFL Biosciences was awarded a €1,500,000 innovation advance on February 20, 2023 under Programme d’Investissement d’Avenir 4 from the France 2030 plan. €1.05 million was received as a recoverable advance when the financing contract was signed, with the balance to be made available when requested by NFL Biosciences upon completion of the study. In addition, around 55% of the €3.1m of funds raised on January 31, 2023 has been allocated to finalizing this Phase II/III clinical trial. Together, these resources will make it possible to finalize the CESTO II study. Progress with the PRECESTO clinical trial to demonstrate the potential complementarity of NFL-101 with other smoking cessation treatments In September 2022, NFL Biosciences obtained the necessary regulatory authorizations from the ANSM and CPP to carry out the PRECESTO phase IIa clinical trial. Its main objective is to validate the potential complementarity of NFL-101 with other smoking cessation treatments, and particularly nicotine substitutes (transdermal patches, tablets, gum, inhalers and nicotine sprays), with a view to developing an innovative treatment method combining NFL-101 with other smoking cessation methods. The PRECESTO study targets 34 smokers who do not wish to quit and have high smoking satisfaction. It compares the ability of NFL-101 to reduce cigarette satisfaction and craving with placebo. Volunteer recruitment started up in February 2023 and is still underway. The initial results are expected for the third quarter of 2023. This study could increase the attractiveness of NFL-101 to pharmaceutical companies, especially those marketing smoking cessation drugs. In terms of funding for PRECESTO, NFL Biosciences was awarded a €200,000 grant (non-refundable) on January 17, 2023 under Programme d’Investissement d’Avenir 4 from the France 2030 plan, awarded jointly by the French State and the Occitanie Region. In addition, around 20% of the €3.1m of funds raised on January 31, 2023 have been allocated to carrying out this Phase IIa clinical trial. Together, these resources will make it possible to finalize the PRECESTO study, which is based on a format and protocol that limits the costs involved. Co-development agreement continuing to move forward for NFL-301, a drug candidate to reduce alcohol consumption In February 2022, NFL Biosciences set up a co-development agreement with ATHENA Pharmaceutiques, a market leader for the development and manufacturing of oral delivery drugs, to develop and produce NFL-301, a natural drug candidate from NFL Biosciences aimed at reducing alcohol consumption. The development of the formulation was launched during the first quarter of 2022. Under this partnership, ATHENA Pharmaceutiques will manage the development and manufacturing of NFL-301, while NFL Biosciences will draw up and lead the clinical program, which is expected to be launched in the United States over the coming months. The partnership aims to develop NFL-301 at least until its placebo-controlled efficacy has been demonstrated as a treatment for reducing alcohol consumption. For the advancement of the NFL-301 project, from product formulation to clinical trial authorization, NFL Biosciences obtained a €200,000 innovation advance as part of Programme d'Investissement d'Avenir 4 from the France 2030 plan. €140,000 was received as a recoverable advance when the support contract was signed on February 20, 2023, with the balance to be made available when requested by NFL Biosciences upon authorization of the clinical trial. In addition, by allocating around 15% of the funds raised on January 31, 2023 to this project, NFL Biosciences will be able to continue developing NFL-301 and file a pre-IND application with the FDA prior to a future clinical trial application. Intellectual property extended with a patent registered in China and South Korea and a new patent application submitted in the United States NFL Biosciences has continued moving forward with its intellectual property management and patent protection strategy, securing exclusive rights to its drug candidate NFL-101 through two patent families, covering an “aqueous extract of tobacco leaves and its use for the treatment of dependence”. The innovation that NFL-101 is based on is already protected through to 2036 in France and the United States, in addition to China (since April 2022) and South Korea (since May 2022). National registration applications are still in the review phase in the following regions and countries: Canada, Australia, Europe, Brazil, India, Indonesia, Philippines, United Arab Emirates and Nigeria. In addition, a new patent application, corresponding to a third patent family, was submitted in October 2022 in the United States and will be extended to cover other countries in line with the intellectual property protection strategy put in place. This application aims to protect the administration of NFL-101 in association other smoking cessation treatments and particularly nicotine substitutes. Partnership with Themis Medicare to develop NFL-101 in India In October 2022, NFL Biosciences set up a partnership with Themis Medicare Ltd to develop NFL-101 on the Indian market. Themis Medicare is a pharmaceutical company headquartered in Mumbai with a legacy of over 50 years of making new treatment options available to patients. India has approximately 267 million smokers, and their options for smoking cessation are very limited. Diversified sources of financing set up at the start of 2023: cash requirements covered through to the third quarter of 2024 At the start of 2023, NFL Biosciences successfully rolled out its financing strategy by applying for various grants and cash advances, and by calling on the financial markets. In total, €4.2m were received during the first quarter of 2023 and €0.7m are still to be received as findings are generated confirming the success of the trials, representing a total secured amount of €4.9m. This has enabled NFL Biosciences to secure progress of the company´s priority projects, and it has a cash horizon that now runs through to the third quarter of 2024. Collaboration with the CEA to study the mechanism of action of NFL-101 At the start of February 2023, NFL Biosciences set up a research partnership with the French Alternative Energies and Atomic Energy Commission (CEA) to study the mechanism of action of its drug candidate NFL-101. This study, scheduled to run for nine months, is being led by the CEA’s Paris-Saclay Pharmacological Neuroimaging team. It will focus on following, by positron emission tomography (PET) imaging, the modifications in the cerebral function associated with the development of tobacco addiction in mice, in order to highlight the central effects of NFL-101 treatment. Governance changes NFL Biosciences’ Board of Directors acknowledged Mr Joël Besse’s resignation from his positions as a Company director and Chairman of its Board of Directors on February 27, 2023. The Board of Directors decided to appoint Mr Ignacio Faus, the Company’s Chief Executive Officer, as Chairman of the Board of Directors for a period that will not exceed his term of office as a director, i.e. through to the end of the General Meeting held in 2024 to approve the financial statements for the year ending December 31, 2023. 2022 full-year earnings The full-year financial statements for 2022 (January 1 2022 – December 31, 2022), prepared in accordance with French GAAP, were approved by the Board of Directors during its meeting on April 24, 2023. The procedures to audit the annual accounts have been completed. The statutory auditors’ reports will be issued when the 2022 Annual Report is published. Corporate accounts (€)December 31, 2021December 31, 2022Net revenues--Total operating income3922EBIT(901,867)(3,083,170)Financial income (expense)(217,643)182,831Non-recurring income (expense)-39,025Net income(978,243)(2,443,484) Shareholders’ equity3,287,481843,996Intangible assets (patents)124,034135,784Liabilities Of which financial liabilitiesOf which operating liabilities 270,74985,007185,7421,478,51083,2561,395,254Cash and cash equivalents3,039,5701,053,581Balance sheet total3,685,2072,395,484 In 2022, NFL Biosciences recorded €22 of operating income, compared with €39 in 2021. Still in the clinical trials development stage, NFL Biosciences did not record any revenues during the last two years. In line with the resources allocated to drive progress with the programs presented above, and the Company’s operations, EBIT came to €(3.1)m in 2022, compared with €(0.9)m in 2021. Payroll and social security contributions totaled €0.7m for four people at December 31, 2022, compared with €0.3m for three people at the end of 2021. In 2022, NFL Biosciences reported a research tax credit (CIR) of €0.4m, compared with €0.1m in 2021, with this change reflecting the ramping up of its research programs. Financial income and expenses for 2022 totaled €0.2m, compared with €(0.2)m in 2021, reflecting the reversal of the provision for the NFL Australia receivables recorded in the accounts in 2021, following the completion of the process to shut this entity down. As a result, NFL Biosciences recorded €(2.4)m of net income, compared with €(1.0)m in 2021. As of December 31, 2022, the Company had €0.8m of shareholders’ equity and €1.0m of cash. The total amount of liabilities at December 31, 2022 came to €1.5m, with €0.1m of financial liabilities and €1.4m of operating liabilities. These cash and liability figures do not take into account the various financing facilities set up in 2023 as presented above. Outlook for 2023 The initial results from the two clinical studies underway are expected to be available in the third quarter of 2023 (PRECESTO) and the fourth quarter of 2023 (CESTO II). Alongside this, NFL Biosciences has submitted a request for scientific advice to the EMA with a view to determining the future development of NFL-101 before its marketing authorization. This scientific advice will be issued in the second quarter of 2023. NFL BIOSCIENCES has also opened talks with several pharmaceutical companies looking into a future partnership for NFL-101. Once the PRECESTO and CESTO II results have been obtained, these discussions could be accelerated. The collaboration with CEA Paris-Saclay, which aims to make progress with the understanding of the mechanism of action of NFL-101, will continue moving forward in 2023. Understanding NFL-101’s mechanism of action is considered to be a very important element for several pharmaceutical companies. Lastly, for NFL-301, the collaboration with ATHENA Pharmaceutiques is moving forward in line with the action plan. As the priority of this project is in the American market, discussions will be launched in 2023 with the FDA to clearly define the clinical development pathway. Non-dilutive financing options in the United States could then be available. NFL BIOSCIENCES has a cash horizon through to the third quarter of 2024 and will continue to benefit from an organization with limited fixed costs. Looking further ahead, NFL Biosciences will need additional financing which, independently or combined, may come from (1) capital increases, (2) non-dilutive financing and (3) partnerships with pharmaceutical companies. Next financial date: 2023 first-half earnings: September 19, 2023 (before start of trading). About NFL Biosciences NFL Biosciences is a biopharmaceutical company based in the Montpellier area which develops botanical drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, natural, safer and more effective therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, called NFL-101, is a standardized, nicotine free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who want to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorder. The shares of NFL Biosciences are listed on Euronext Growth Paris (FR0014003XT0 – ALNFL). Find out more at www.nflbiosciences.com Contacts Bruno Lafont – info@nflbiosciences.com - +33 4 11 93 76 67 Agence Calyptus – nflbiosciences@calyptus.net - +33 1 53 65 68 68 Attachment NFLBio_CP_RA_2022_EN_DEF

Very successful capital increase for NFL Biosciences with over €3 million raised Strong success of the placement with professional investors with a diversified base of French and international investors for an amount of €2.45 million Exceptional participation of retail investors via the PrimaryBid platform with an offer oversubscribed nearly 3 times and almost 1,000 orders received, for a total amount of €1.6M, with €0.6M being allocated to the retail tranche1.Subscription price set at €2.23 per new share, in the middle of the offering range.Cash horizon secured for more than 12 months, allowing NFL Biosciences to reach in 2023 the key milestones of the two ongoing studies on NFL-101 as a smoking cessation aid.Settlement and delivery of the new shares on February 2, 2023. NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company that is developing botanical drugs for the treatment of addictions (the “Company”), is today announcing that it has successfully completed its fundraising round for a total of 3,059,910.11 euros through capital increases with preferential subscription rights waived for current shareholders. The offer was subscribed, on the one hand, by professional investors for 2.5 million euros, and, on the other hand, by retail investors through the PrimaryBid platform for 0.6 million euros (the “Transaction”). Ignacio Faus, NFL Biosciences CEO: “On behalf of NFL Biosciences, I would like to warmly thank all of the professional investors and the many retail investors, through PrimaryBid, who took part in this fundraising round. We have now secured the resources needed to reach the validation milestones of our two main clinical programs on NFL-101 in 2023, and we will also be able to move forward with the development of NFL-301. As always, we will take the greatest care to effectively allocate these resources and we are confident that we will be able to demonstrate the efficacy of NFL-101 in helping people stop smoking”. Allocation of the funds Specifically, the funds raised in connection with the Transaction will make it possible to supplement the financing for the CESTO II phase II/III trial, aiming to demonstrate the efficacy of its botanical drug candidate NFL-101 for smoking cessation, and the PRECESTO trial, assessing the potential of NFL-101 to be associated with nicotine replacement therapies, as well as the continued development of NFL-301, aimed at reducing alcohol consumption. CESTO II • The CESTO II trial is progressing in line with the schedule set, with 75% of the 318 smokers recruited at the nine clinical investigation centers that are taking part in the study. NFL Biosciences expects to finalize recruitments at the end of the second quarter, which would enable results to be obtained for the main criteria at the end of 2023. CESTO II’s objectives are to select the best dose and assess the efficacy of NFL-101 versus placebo. The primary end-point for assessment is the subjects’ continued abstinence for four weeks (US Food & Drug Administration (FDA) accepted end-point). Many other secondary end-points will also be assessed, including the subjects’ continued abstinence for six months (European Medicines Agency (EMA) accepted end-point), the number of cigarettes smoked, withdrawal symptoms and level of craving. About 55% of the funds raised will be allocated to finalizing this Phase II/III clinical trial. PRECESTO • This Phase IIa clinical trial aims primarily to validate the complementarity of NFL-101 with other smoking cessation treatments and particularly nicotine replacement therapies (transdermal patches, tablets, chewing gums, inhalers and nicotine sprays) with a view to developing an innovative treatment method by associating NFL-101 with other smoking cessation methods. The PRECESTO trial will compare against a placebo the capacity of NFL-101 to reduce smoking satisfaction and cravings. This is a randomized, double-blind trial that will include 34 smokers who are not looking to stop smoking and get great satisfaction from smoking with a cross-over design. This trial is expected to further strengthen the appeal of NFL-101 for pharmaceutical companies that sell smoking cessation drugs and could be interested in taking out licenses. About 20% of the funds raised will be allocated to putting in place and carrying out this Phase IIa clinical trial. The PRECESTO trial results are expected for the third quarter of 2023. NFL-301 • This natural drug candidate to reduce alcohol consumption is subject to a co-development agreement with ATHENA Pharmaceutiques, set up in February 2022. Under this partnership, ATHENA Pharmaceutiques, a market leader for the development and manufacturing of oral delivery drugs, will manage the development and manufacturing of NFL-301, while NFL Biosciences will draw up and lead the clinical program, which could be launched in the United States over the coming months. By allocating about 15% of the funds raised to this project, NFL Biosciences will be able to continue developing NFL-301 and file a pre-IND application with the US Food and Drug Administration (FDA) prior to a future clinical trial application. The partnership aims to develop NFL-301 at least until its placebo-controlled efficacy has been demonstrated as a treatment for reducing alcohol consumption. NFL Biosciences and ATHENA Pharmaceutiques will make a joint investment and will share future revenues based on their respective investments. The balance of the funds raised, approximately 10%, will be allocated to the day-to-day operations of the Company. Before carrying out this round of fundraising, NFL Biosciences’ cash horizon was the end of the second quarter of 2023. Considering the current level of cash and the estimated proceeds from this round of fundraising, NFL Biosciences is pushing back its cash horizon to March 2024. In addition, two other applications for subsidies for a combined total of 1.7 million euros are currently being reviewed by Bpifrance, with an outcome expected in the first quarter of 2023, thus extending the cash horizon even further. NFL Biosciences will also continue to apply for non-dilutive financing solutions with French and European institutions. Reminder of the Transaction’s key features The Transaction was put in place and carried out under the 10th, 12th and 13th resolutions from the Company’s Extraordinary General Shareholders’ Meeting on May 25, 2022 (the “General Meeting”) at a price of 2,23 euros per share, representing a discount of 24.87% compared to the volume-weighted average price of NFL Biosciences shares over the last 5 trading sessions (i.e. from Monday, January 23 to Friday, January 27, 2023) equal to 2.9680 euros and 29.21% compared to the closing price of NFL Biosciences shares on Monday, January 30, 2023 which is 3.15 euros. The Transaction, for a total of 3,059,910.11 euros, including the issue premium, was carried out by issuing, with preferential subscription rights waived, 1,372,157 new ordinary shares, representing 26.2% of the Company’s share capital prior to the Transaction, with: (i) 1,097,726 new shares issued for a total of 2,447,928.98 euros (including the issue premium), representing 80% of the Transaction, for professional investors under the 10th and 12th resolutions from the General Meeting (the “Reserved Offer”), and (ii) 274,431 new shares issued for a total of 611,981.13 euros (including the issue premium), representing 20% of the Transaction, for retail investors that subscribed through the PrimaryBid platform (the “PrimaryBid Offer”). The settlement-delivery of these new shares and their admission to Euronext Growth Paris under ISIN FR0014003XT0 will take place on February 2nd, 2023. The newly issued shares will be assimilated with the existing shares and will accrue dividends immediately. It is reminded that in connection with the Transaction, NFL Biosciences has made a commitment, on the one hand, to not carry out any capital increase based on new shares for a period of 6 months from the completion of the Transaction without prior approval from Invest Securities and, on the other hand, to not issue any bonds that could be exchanged for or converted into new shares, whether or not these are combined with stock warrants, until December 31, 2023. Following the Transaction, the Company’s share capital will represent 198,203 euros, split into 6,606,769 ordinary shares with a par value of 0.03 euros, all of the same category. The breakdown of the Company’s shareholding structure before the Trasaction was as follows: On a non-diluted basis On a diluted basis In quantity of shares In % of ownership In quantity of shares In % of ownership Joël BESSE 1,111,253 21.2% 1,361,253 17.9% Bruno LAFONT 325,279 6.2% 1,075,279 14.1% Gérard LEDUC 76,550 1.5% 1,076,550 14.1% Family MEREAU 544,588 10.4% 669,588 8.8% Eric MOREL D'ARLEUX 372,803 7.1% 372,803 4.9% Family NICOLAS 275,320 5.3% 275,320 3.6% Other private investors 775,246 14.8% 1,036,976 13.6% Public 1,753,573 33.5% 1,753,573 23.0% Total 5,234,612 100.0% 7,621,342 100.0% The breakdown of the Company’s shareholding structure following the Transaction is as follows: On a non-diluted basis On a diluted basis In quantity of shares In % of ownership In quantity of shares In % of ownership Joël BESSE 1,111,253 16.8% 1,361,253 15.1% Bruno LAFONT 325,279 325,279 4.9% 1,075,279 Gérard LEDUC 76,550 76,550 1.2% 1,076,550 Family MEREAU 544,588 544,588 8.2% 669,588 Eric MOREL D'ARLEUX 372,803 372,803 5.6% 372,803 Family NICOLAS 275,320 275,320 4.2% 275,320 Other private investors 775,246 775,246 11.7% 1,036,976 Public 3,125,730 47.3% 3,125,730 34.8% Total 6,606,769 100.0% 8,993,499 100.0% It is specified that subscriptions, for a cumulative amount of €2.2 million, were subject to a remuneration of 5% of the amount subscribed. Transation partners Investment services provider and bookrunner Consulting Legal advisory Financial communication Disclaimer Pursuant to the provisions of Article 1(4) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, the Transaction did not give rise to the publication of a Prospectus subject to approval by the Autorité des Marchés Financiers (AMF). This press release does not constitute a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, as amended, or a public offering. In certain countries, the distribution of this press release may be subject to specific regulations. Consequently, persons in such jurisdictions where the press release is released, published or distributed must inform themselves about and comply with such legislation and regulations. This press release constitutes a promotional communication and not a prospectus within the meaning of the Prospectus Regulation. This press release does not constitute an offer to sell securities or a solicitation for an offer to purchase or subscribe for securities in the United States of America. The shares or any other securities of the Company may only be offered or sold in the United States of America following a registration under the U.S. Securities Act of 1933 (the “Securities Act”), as amended, or pursuant to an exemption from such registration requirement. The Transaction may exceptionally be aimed at a limited number (i) of qualified institutional buyers in the United States of America (“qualified institutional buyers” or “QIB”) within the meaning of Rule 144A (“Rule 144A”) under the U.S. Securities Act of 1933, as amended and/or (ii) institutional accredited investors (“institutional accredited investors” or “IAI”) within the meaning of Rule 501 (a) (1), (2), (3), (7), (8), (12) or (13) of Regulation D of the Securities Act pursuant to an exemption from registration in accordance with Section 4(a)(2) of the Securities Act, notably within the framework of the Issue Reserved for a Category of Persons, subject to entering into the categories determined in accordance with Article L. 225-138 of the French commercial code (Code de commerce). The shares of the Company will only be offered or sold outside the United States of America and in the framework of offshore transactions in accordance with Regulation S of the Securities Act. The Company does not intend to register the Transaction in whole or in part in the United States of America or to make a public offering in the United States of America. With respect to Member States of the European Economic Area, no action has been or will be taken to permit a public offering of the securities covered by this press release requiring the publication by the Company of a prospectus in a Member State other than France. Accordingly, the shares of the Company may not be offered and will not be offered in any Member State other than France, except in cases not requiring the publication by the Company of a prospectus under the Prospectus Regulation and/or the regulations applicable in that Member State. This press release can be distributed (A) outside the United States in accordance with Regulation S of the US Securities Act solely to (i) persons in the United Kingdom (a) who are investment professionals within the meaning of Section 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as currently in force, hereinafter the “Financial Promotion Order”), or (b) high net worth entities referred to in Section 49(2) (a) to (d) of the Financial Promotion Order, or (c) persons to whom an invitation or inducement to engage in investment activities (within the meaning of Section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities of the Company or any member of its group may lawfully be communicated, directly or indirectly; (ii) persons in any other Member States of the European Economic Area who are “qualified investors” within the meaning of Article 2(e) of the Prospectus Regulation (Regulation (EU) 2017/1129, as amended); (iii) certain qualified and/or institutional investors in other selected jurisdictions, in accordance with the restrictions applicable; and persons in the United States who are “qualified institutional buyers”, within the meaning and on the basis of Rule 114A of the US Securities Act or another exemption from registration or a transaction that is not subject to registration under the US Securities Act. About NFL Biosciences NFL Biosciences is a biopharmaceutical company based in the Montpellier area which develops botanical drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, natural, safer and more effective therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, called NFL-101, is a standardized, nicotine-free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who want to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorders. The shares of NFL Biosciences are listed on Euronext Growth Paris (FR0014003XT0 – ALNFL). Find out more at www.nflbiosciences.com Contacts Bruno Lafont – info@nflbiosciences.com - +33 4 11 93 76 67 Agence Calyptus – nflbio@calyptus.net - +33 1 53 65 68 68 (1) It is reminded that the PrimaryBid Offer may only represent a maximum of 20% of the amount of the Global Offer. Attachment 20230131_NFLBiosciences_CP_Succès-levée-de-fonds_EN_DEF